Request an Appointment

Cholangiocarcinoma (bile duct cancer)

Clinical trials

Below are current clinical trials.


7 studies in Cholangiocarcinoma (bile duct cancer)
(open studies only).

Filter this list of studies by location, status and more.

  1. Circulating Tumor Cells in Patients with Cholangiocarcinoma

    Rochester, Minn.

    The overall goal of this research is to measure the circulating tumor cell in the peripheral blood and investigate the association between circulating tumor cell level and tumor characteristics and prognosis.

     

  2. Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy

    Scottsdale/Phoenix, Ariz.

    The purpose of this study is evaluate the efficacy of INCB054828 in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.

  3. Study of CX-4945 in Combination with Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

    Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

    This study considers the safety and tolerability of increasing doses of CX-4945 in combination with gemcitabine plus cisplatin to determine the maximum tolerated dose (MTD), followed by a randomized study that compares antitumor activity in cholangiocarcinoma patients receiving the standard of care gemcitabine plus cisplatin versus CX-4945 at the combination MTD with gemcitabine plus cisplatin.

  4. A Study to Better Understand Carcinogenetic Progression in Cholangiocarcinoma

    Rochester, Minn.

    The purpose of this study is to develop a better understanding of the carcinogenetic progression in cholangiocarcinoma and also to develop more accurate diagnostic tests.

  5. A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

    Scottsdale/Phoenix, Ariz., Rochester, Minn.

    This is an open label, multi-center, Phase Ib dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib. A study cycle will consist of daily and continuous oral administration of BBI608 for four weeks (28 days) in combination with FOLFOX6 with and without bevacizumab, or CAPOX or FOLFIRI with and without bevacizumab, or regorafenib.

  6. Tissue and Blood Registry for Individuals with Liver and Biliary Tumors

    Jacksonville, Fla.

    This study will collect and store samples of tissue and blood for current and future research studies on Liver and Biliary Tumors.

  7. Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

    Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla.

    This pilot phase II trial studies how well ponatinib hydrochloride works in treating patients with biliary cancer that has spread to other places in the body and that have alterations (fusions) in a gene known as fibroblast growth factor receptor 2 (FGFR2). Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Request an Appointment at Mayo Clinic
Locations, travel & lodgingResearch
April 25, 2017
References
  1. AskMayoExpert. Cholangiocarcinoma. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2016.
  2. Feldman M, et al. Tumors of the bile ducts, gallbladder and ampulla. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 10th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. http://www.clinicalkey.com. Accessed Feb. 22, 2016.
  3. Rizvi S, et al. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion. 2014;89:216.
  4. Zaydfudim VM, et al. Hilar cholangiocarcinoma. Surgical Oncology Clinics of North America. 2014;23:247.
  5. Riggin EA. Allscipts EPSi. Mayo Clinic, Rochester, Minn. Oct. 27, 2016.
  6. Brown AY. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Nov. 3, 2016.
  7. Smoot RL (expert opinion). Mayo Clinic, Rochester, Minn. March 23, 2017.
  8. Choi J, et al. Aspirin use and the risk of cholangiocarcinoma. Hepatology. 2016;64:785.
  9. Doherty B, et al. Update on the diagnosis and treatment of cholangiocarcinoma. Current Gastroenterology Reports. 2017;19:2.
  10. Borad MJ, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PloS Genetics 2014;10:e1004135. http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1004135. Accessed Feb. 27, 2017.
  11. Barbara Woodward Lips Patient Education Center. Surgery on the extrahepatic bile duct, duodenum, papilla, or pancreas. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2012.
  12. Merck Manual Professional Version. Tumors of the gallbladder and bile ducts. https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/gallbladder-and-bile-duct-disorders/tumors-of-the-gallbladder-and-bile-ducts#v902250. Accessed Feb. 28, 2017.
  13. Bergquist JR, et al. Implications of CA19-9 elevation for survival, staging and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis. Journal of Surgical Oncology. 2016;114:475.

Related

Cholangiocarcinoma (bile duct cancer)

Research: It's All About Patients

Diagnosis & treatment